Some subunits of the SWI/SNF complex function as tumor suppressors. However, underlying mechanisms are still incompletely defined. Here, we show that Srg3, a mouse homolog of BAF155 that function as a core subunit of this complex, suppresses tumorigenesis in vivo. DNA damage signals promoted Srg3 degradation by inducing p53. Deficiency of Srg3 promoted G1 cell-cycle arrest, but antagonized apoptotic response to DNA damage by robustly inducing p53 and p21 proteins. Srg3 heterozygous mice were prone to sarcoma formation, which was further enhanced by haploinsufficiency of p53. These tumors highly expressed p53 and p21 but lacked Srg3 expression. Our results establish a novel function of Srg3 in tumor suppression and provide insights into genetic pathways dictating tumor suppression by the SWI/SNF complex.
Introduction
The mammalian SWI/SNF complexes induce chromatin reorganization by destabilizing nucleosome-DNA interactions in an ATP-dependent manner (de la Serna et al., 2006) . They are made up of approximately 10-12 subunits depending on cellular context. Among them, BRM and BRG1 are alternative catalytic subunits with ATPase activity. BAF155 (Srg3), BAF170 and BAF47 (Snf5) subunits are considered core subunits of the SWI/ SNF complex (Phelan et al., 1999) .
Some subunits of the SWI/SNF complexes retain tumor suppressor activities (Roberts and Orkin, 2004) . Somatic mutations of BRG1 or BRM are common in a number of human cancers and primary tumors (Wong et al., 2000; Decristofaro et al., 2001) . Snf5 is also consistently deleted or mutated in malignant rhabdoid tumors (Versteege et al., 1998; Biegel et al., 1999) . Consistently, Brg1 heterozygous mice are predisposed to subcutaneous glandular tumors with histological features similar to breast adenocarcinomas (Bultman et al., 2000) . High incidence of mammary tumors or lung cancers was also reported in the Brg1 mutant mice (Bultman et al., 2008; Glaros et al., 2008) . Snf5 heterozygous mice are prone to tumors resembling malignant rhabdoid tumors (Klochendler-Yeivin et al., 2000; Roberts et al., 2000; Guidi et al., 2001) . In another study, conditional deletion of Snf5 also leads to either CD8 þ mature T-cell lymphomas or, less commonly, rhabdoid tumors with 100% penetrance (Roberts et al., 2002) .
Several potential mechanisms of tumor suppression by the SWI/SNF complexes have been suggested. These complexes are important regulators of cell-cycle progression (Roberts and Orkin, 2004) . They physically associate with retinoblastoma (RB) to promote RBinduced cell-cycle arrest by repressing the E2F-dependent transcription (Dunaief et al., 1994; Trouche et al., 1997) . BRG1 also can inhibit RB phosphorylation by upregulating the cyclin-dependent kinase inhibitor p21 WAF1/CIP1 (p21). Re-expression of BRG1 in the BRG1-deficient cancer cell lines restores RB function, repressing E2F targets, such as cyclin E (Hendricks et al., 2004) . Although SNF5 is dispensable for RB-induced cell-cycle arrest, re-expression of SNF5 into malignant rhabdoid tumor cell lines leads to G1 cell-cycle arrest, possibly through p16
INK4a induction and Cyclin D1 repression (Betz et al., 2002; Zhang et al., 2002) . Furthermore, several reports suggest that ablation of p53 dramatically accelerates tumor formation caused by Snf5 deficiency (Isakoff et al., 2005; Klochendler-Yeivin et al., 2006) . In the double knockout mice, it appears that the tumor spectrum is initially determined by Snf5 loss and then p53 deficiency may promote tumorigenesis. Nonetheless, the molecular mechanisms dictating tumor suppression by the SWI/SNF complex are still poorly understood.
p53 has been regarded as a gatekeeper to eliminate potentially cancer-prone cells (Vousden and Lu, 2002) . Aberrant p53 pathway promotes tumor development by disrupting mechanisms that prevent the expansion of damaged cells, mainly apoptosis and cell-cycle arrest (Symonds et al., 1994; Schmitt et al., 2002) . The fates of DNA-damaged cells are determined depending on the relative levels of p53 downstream effectors. p21 is a major p53 target that is initially known to block cell-cycle progression. High levels of p21 can antagonize p53-induced apoptosis during DNA damage response (Gartel and Tyner, 2002; Vousden, 2006) . Thus, p53 can either suppress or promote cell death by controlling the abundance of p21 and other death-related molecules (Vousden and Lu, 2002; Vousden, 2006) . Disruption of p53 or p21 increases the sensitivity to DNA damageinduced apoptosis in mouse embryonic fibroblasts (MEFs) or HCT116 human colorectal carcinoma cell line (Polyak et al., 1996; Waldman et al., 1996; Bunz et al., 1998; Chan et al., 2000; Shibue et al., 2003) . In addition, p53 point mutants that fail to transactivate p21 induce apoptosis more potently, compared with wild-type (WT) p53 (Kaneuchi et al., 1999) .
There are many pieces of evidence that SRG3 may also retain a tumor suppressor function. BAF155, a human homolog of Srg3, maps to chromosome 3p23-21, which is frequently lost in multiple human cancers (Ring et al., 1998) . Loss of BAF155 has been reported in several tumor cell lines, including A427 lung cancer cell line (Decristofaro et al., 2001) . In addition, Srg3 is crucial for the stability and nuclear localization of other subunits of the SWI/SNF complex, including Brg1 and Snf5 tumor suppressors (Chen and Archer, 2005; Moshkin et al., 2007; Sohn et al., 2007; Yang et al., 2007) . In this study, therefore, we aimed to resolve the roles of Srg3 in malignant transformation.
Results
Srg3 is repressed in response to DNA damage in a p53-dependent manner To explore how Srg3 expression is controlled upon DNA damage, WT and p53 À/À C57BL/6 mice were g-irradiated (6 Gy) and kinetics of Srg3 expression in various lymphoid organs were assessed by immunoblotting. As expected, p53 proteins were strongly induced after g-irradiation in the WT, but not p53 À/À , mice (Figure 1a) . Regardless of the types of organ, the level of Srg3 proteins gradually decreased in WT cells, whereas it remained unchanged in p53 À/À cells ( Figure 1a ). Brg1, another core subunit with ATPase activity, was also similarly downregulated. Commonly used chemotherapeutics that induce DNA damage, such as doxorubicin (DOX), etoposide (ETO) and cisplatin (CIS) also gradually downregulated Srg3 expression in WT, but not p53 Figure S1 ). Srg3 expression was controlled at the post-transcriptional level as SRG3 Figure 1 Srg3 is repressed in response to DNA damage in a p53-dependent manner. (a) WT and p53 À/À C57BL/6 mice were g-irradiated (6 Gy) and single cell suspensions were prepared from thymus (left), lymph nodes (middle) and spleen (right) after 0, 3, 6 or 12 h. Immunoblot analysis was performed using whole-cell extracts from the cells to assess the level of Srg3, Brg1, p53 and Actin proteins. Actin served as a loading control. (b-d) WT and p53 À/À MEFs were treated with doxorubicin (DOX) (DOX, 0.2 mg/ml) (b), etoposide (ETO, 20 mM) (c) or cisplatin (CIS, 10 mM) (d) for various periods of time as indicated and immunoblot analysis was performed to assess the level of Srg3, p53 and Actin proteins. Actin served as a loading control. (e) WT and Myc-Srg3 MEFs were cultured in the presence or absence of DOX (0.2 mg/ml) for 12 h and immunoblotting was performed to detect the levels of total SRG3 or exogenous Myc-Srg3 proteins using antibodies against endogenous Srg3 or Myc epitope, respectively. Actin served as a loading control. (f) 293T cells were co-transfected with fixed amount of Myc-Srg3 and increasing amounts of FLAG-p53 and subjected to immunoblotting. (Figure 1e ). This was also reproducible when CAG-driven Myc-Srg3 was overexpressed with increasing amounts of FLAG-p53 (Figure 1f ). However, p53 or DOX could not inhibit Srg3 expression in the presence of MG132 (Supplementary Figures S3a-b) , a proteasome inhibitor. Expression of Siah-1, a p53-inducible E3 ubiquitin ligase (Liu et al., 2001; Fiucci et al., 2004) , downregulated Srg3 proteins in a dose-dependent manner, which was partially inhibited in the presence of MG132 (Supplementary Figures S4a-b) . However, Siah-1DN, a dominantnegative mutant of Siah-1 (Hu and Fearon, 1999) , inhibited p53-mediated Srg3 degradation (Supplementary Figure S4c ). Collectively, these observations raise the possibility that p53 reduces Srg3 expression by means of proteasomal pathway by inducing Siah-1 proteins.
Srg3 deficiency leads to growth retardation and G1 cell-cycle arrest Because Srg3 expression was repressed by p53 during DNA damage response, we next assessed the effect of Srg3 deficiency on various aspects of cellular physiology. For this purpose, we established NIH3T3 cell lines stably expressing empty vector (control) or small hairpin RNAs against Srg3 transcripts. The efficiency of Srg3 knockdown (Srg3-KD) was confirmed by immunoblot analysis (Figure 2a ). Srg3-KD led to morphological changes, including flattened and rounded shape, and decreased growth rate (Figures 2b-c) . Flow cytometric analyses of cellular DNA contents showed that Srg3 deficiency led to a modest but consistent increase in the fraction of cells at G1 phase by about 8.8% and corresponding decrease in the percentage of cells at G2/M phase by about 9.5% (Figures 2d and e) . The percentage of S-phase population was slightly decreased upon Srg3-KD (21.47 ± B5.71 vs 18.71 ± B3.69), although the difference was within error ranges, showing very mild, incomplete G1 arrest. Upon DOX treatment, Srg3 deficiency did not significantly impair induction of G2/M block but relative fraction of cells at G1 phase of cell cycle was also consistently higher in Srg3-KD cells, compared with controls. These results suggest that Srg3 deficiency promotes a mild G1 cell-cycle arrest. To more clearly resolve this, control and Srg3-KD cells were serum starved to arrest cells at G1 phase, and then cultured further after re-addition of serum for various periods of time. Control cells started to exit G1 cell-cycle arrest between 12 and 15 h and an appreciable portion of them progressed to G2/M phase by 18 h. However, exit from G1 phase was delayed in Srg3-KD cells as they began to exit G1 phase between 18 and 20 h (Figures 2f   and g ). Collectively, these results indicate that Srg3 deficiency impairs cell-cycle progression by inducing G1 cell-cycle arrest.
Repression of Srg3 renders cells resistant to DNA damage-induced cell death with intact g-H2AX induction
The ability of p53 to engage apoptotic pathways is likely to be particularly important for its tumor-suppressive activity in vivo. Because Srg3 expression was reduced by p53, we next investigated whether Srg3 is implicated in the cell fate decision upon DNA damage signals. Control and Srg3-KD cells were treated with various concentrations of DOX and then cell death was examined. As shown in Figure 3a , Srg3-KD cells were more resistant to DNA damage-induced cell death, compared with controls. Similar results were obtained when cell death was induced by ETO ( Figure 3b ). This pro-survival effect of Srg3 deficiency was not cell type-specific, because Srg3 þ /À MEFs were also more resistant to ETO-induced cell death than WT MEFs ( Figure 3c ).
As one of immediate cellular responses to DNA damage, the histone variant H2AX becomes extensively phosphorylated at serine 139, resulting in g-H2AX foci adjacent to double strand breaks (DSBs) (Rogakou et al., 1998) . Thus, the formation of g-H2AX foci has been used as a very sensitive marker for the occurrence of DSBs (Rothkamm and Lobrich, 2003) . To assess whether the induction of g-H2AX is impaired in our system, control and Srg3-KD cells were treated with DOX for different periods of time (0, 0.5, 1 and 2 h) or at different concentrations (1 and 0.5 mg/ml), and g-H2AX was detected by confocal microscopy. As shown in Figure 3d and Supplementary Figure S5 , the formation of g-H2AX foci was similarly induced after DNA damage in both cells. Taken together, these results suggest that Srg3 deficiency prevents DNA damageinduced cell death by means of distinct pathways from g-H2AX induction or DNA repair.
Srg3 deficiency leads to upregulation of p53 and p21 expression Activation of p53 signaling pathways has critical roles in dictating cellular responses to DNA damage. Therefore, it was possible that the phenotypes induced by Srg3 deficiency might be attributed to aberrant p53 signaling pathway. To address this possibility, we first examined the kinetics of p53 and p21 induction during DNA damage response in MEFs from WT and Srg3 þ /À mice. Srg3 proteins were approximately two times lower in Srg3 þ /À MEFs relative to the WT MEFs ( Figure 4a ). Upon DOX treatment, p53 and p21 were more robustly induced in Srg3 þ /À MEFs, compared with WT controls (Figure 4b ). It is of note that the p21 proteins were already maintained at high levels in Srg3 þ /À MEFs even before DOX treatment, suggesting that p21 proteins can be upregulated independently of transcriptional activation by p53 (Figure 4b ). These phenomena were not unique to MEFs, because p53 and p21 were also more highly accumulated in response to DOX treatment in the Tumor suppressor function of Srg3 via p21 regulation J Ahn et al
To determine how p21 expression was controlled by Srg3 deficiency, we compared the level of p21 proteins and transcripts in DOX-treated control and Srg3-KD cells. The level of p21 mRNAs induced by DOX treatment was similar in both groups, although p21 proteins were more abundant in the Srg3-KD cells (Figures 4d and e) , suggesting that Srg3 controlled the level of p21 proteins mainly at the post-transcriptional level. To further characterize the effect of Srg3 deficiency on p21 induction, we next measured p21 Tumor suppressor function of Srg3 via p21 regulation J Ahn et al protein stability. Control and Srg3-KD cells were treated with DOX to induce p21 proteins, washed and then the rate of p21 turnover was determined over extended time periods in the presence of cycloheximide. The half-life of p21 was longer in Srg3-KD cells than in control cells, suggesting that Srg3 deficiency led to stabilization of p21 proteins (Figures 4f and g ). However, Srg3 deficiency did not significantly affect the expression of several death-related p53 target genes, including Bax, Apaf1, Killer/DR5 or Survivin (Figure 4h ). Furthermore, there was no significant alteration in the expression of E2F target genes, such as E2F1, Cyclin E1 and Dhfr genes (Supplementary Figure S6) .
Srg3 deficiency inhibits DNA damage-induced cell death in a p53-and p21-dependent manner Because p53 or p21 can antagonize DNA damageinduced cell death, we next explored whether Srg3 deficiency inhibits DNA damage-induced cell death by robustly inducing p53 and p21 proteins. To address this possibility, we produced WT, p53 À/À and p21 À/À MEF cell lines with stable knockdown of Srg3 expression (Figure 5a ). In WT MEFs, Srg3-KD also upregulated p21 proteins similar to Srg3 þ /À MEFs. It is interesting that Srg3 deficiency could upregulate p21 proteins very weakly even in the p53 À/À MEFs, suggesting that p53-independent mechanism can be implicated in p21 induction in Srg3-deficient cells (Figures 4b and 5a) . were treated with DOX at 0.2 mg/ml for various periods of time as indicated. Then, immunoblotting was performed using whole-cell extracts to assess the level of p53, p21, Bax and Actin proteins. Actin served as a loading control. (d, e) Control and Srg3-KD cells were cultured in the presence or absence of DOX (0.4 mg/ml) for 6 h and immunoblotting (d) and reverse transcriptase (RT)-PCR (e) were performed using whole-cell extracts and total RNAs, respectively, prepared from the same cells. (f) Control and Srg3-KD cells were treated with DOX (0.4 mg/ml) for 6 h, washed with phosphate-buffered saline two times and subsequently treated with cycloheximide (CHX) at 100 mg/ml as indicated. Whole-cell lysates were analyzed by immunoblot analysis to assess the levels of p21 and Actin proteins. (g) Summary of the abundance of p21 proteins observed in (f). The band intensity of p21 proteins was measured and normalized against Actin protein level. The level of p21 relative to Actin proteins without CHX treatment was arbitrarily set to 100%. (h) Control and Srg3-KD cells were cultured in the presence or absence of DOX at 0.4 mg/ml for 6 h. Then, RT-PCR analyses were performed to assess the expression of p53 downstream targets.
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This p53-independent mechanism was more prominent when cells were treated with DOX ( Figure 5b ). However, because p21 induction by Srg3 deficiency was much stronger in WT than in p53 À/À MEFs (Figure 5a ), it appears that the major pathway of p21 induction is p53-dependent. Then, we treated these MEF cell lines with DOX or ETO at various concentrations and the degree of apoptosis was measured by flow cytometry. MEFs deficient for either p53 or p21 were highly susceptible to DNA damage-induced apoptosis compared with WT MEFs. However, Srg3 depletion significantly protected WT MEFs from DNA damage-induced apoptosis, but it could not in the absence of either p53 or p21 (Figures 5c  and d) . These results suggest that DNA damage-induced apoptosis is inhibited by Srg3 repression in a p53-and p21-dependent manner.
Subsequently, we examined whether Srg3 deficiency affected cell-cycle progression or apoptosis in a p53-or p21-dependent manner. Srg3 depletion in WT MEFs led to a slight increase in cells at G1 phase of the cell cycle, which was abrogated by loss of p21 or p53 (Figures 5e  and f) . These results suggest that partial G1 cell-cycle arrest by Srg3 deficiency is dependent on p53 and p21.
Haploinsufficiency of both Srg3 and p53 cooperates in tumorigenesis in vivo Increased survival of DNA-damaged cells by Srg3 deficiency led us to assume that Srg3 deficiency might promote malignant transformation in vivo. Apparently, there was no significant difference between WT and Srg3 þ /À C57BL/6 mice, except that Srg3 
Srg3
þ /À mice (11 of 24) developed macroscopic tumors within 11.5 months, whereas 5% (1 of 22) of p53 þ /À mice showed prominent macroscopic tumor development (Figures  6a-b) . Immunohistological analysis showed that five tumors from p53
þ /À mice examined were identified sarcomas, possibly leiomyosarcoma, as they strongly expressed small muscle actin and desmin, but not vimentin or epithelial membrane antigen (Figures 6b-d) . One was lymphoma and five were not identified. Subsequently, we examined p21 expression in primary tumors from p53
þ /À mice. As shown in Figure 6e , p21 proteins were expressed in all tumor samples tested. Furthermore, p53 proteins were highly expressed in several tumors from p53 (Figure 6f ). In contrast, Srg3 proteins were almost absent in all of the primary tumors, suggesting that Srg3 expression might be lost during tumorigenesis (Figure 6f ). Taken together, these results suggest that Srg3 functions as a tumor suppressor in vivo.
Discussion
We observed that Srg3 expression was repressed upon DNA damage signals in a p53-dependent manner (Figure 1 ). Brg1 was also similarly downregulated by p53 induction (Figure 1a) . Because Srg3 was crucial for protecting BRG1 proteins from proteasomal degradation (Sohn et al., 2007) , it is possible that p53-mediated Srg3 degradation indirectly led to depletion of BRG1 proteins. Alternatively, p53 might directly control Brg1 expression. In either case, because the expression of these two core members was inhibited, it is likely that the overall activities of the SWI/SNF complexes might be downregulated by activated p53 during DNA damage response.
Cells with reduced Srg3 expression displayed partial proliferative defects presumably because of impaired G1 to S transition, which was abrogated by loss of p53 or p21 (Figures 2d-f, 5e and f) . Unequivocally, p21 retains the potential to induce cell-cycle arrest mainly at either G1/S or G2/M boundaries . These results suggest that repression of Srg3, or possibly the SWI/SNF complex, might, at least in part, contributes to the G1 cell-cycle checkpoint functions of p53 following DNA damage.
It is not clear how the SWI/SNF complex proteins function as tumor suppressor. We could not observe significant alterations in the expression of E2F-responsive genes by Srg3 deficiency (Supplementary Figure S6) , suggesting that control of RB/E2F function cannot explain the roles of the SWI/SNF complex in tumor suppression. Even though BRG1 was previously reported to reinforce RB-mediated cell-cycle arrest through either physical interaction with RB or p21 induction, leading to G0/G1 arrest by suppressing E2F-regulated genes (Dunaief et al., 1994; Trouche et al., 1997; Strobeck et al., 2000; Hendricks et al., 2004) , it is still controversial whether expression of E2F target genes is altered by loss of BRG1 or SNF5 (Isakoff et al., 2005; Klochendler-Yeivin et al., 2006) . Furthermore, the aberrant RB/E2F pathway or p16
Ink4a expression is not sufficient for accounting for the tumor suppressor activities of the SWI/SNF complex because the spectrum and latency of tumors in mice with inactivation of Rb, p16 Ink4a , Brg1 and Snf5 are very different (Roberts and Orkin, 2004) . In addition, we could not observe any significant defects in g-H2AX induction in the Srg3-KD cells (Figure 3d ). These results suggest that the tumor suppressor function of the SWI/SNF complex is not mediated majorly through DNA repair or genomic instability. Actually, it remains unresolved whether the SWI/SNF complex is essential for maintaining cellular ploidy, genome stability or DNA repair. Some reports have shown that this complex is recruited to the site of DSBs, and inactivation of this complex leads to inefficient DSB repair, leading to genomic instability (Chai et al., 2005; Vries et al., 2005; Klochendler-Yeivin et al., 2006; Park et al., 2006) . However, another report showed that loss of SNF5 does not affect the sensitivity to DNA damaging agents, g-H2AX induction and their recruitment to sites of DNA damage, and that neither BRG1 nor SNF5 colocalizes with g-H2AX foci (McKenna et al., 2008) . DNA repair and DNA damage checkpoint were intact in the absence of SNF5, with no genomic alterations observed in the primary SNF5-deficient malignant rhabdoid tumors (McKenna et al., 2008) .
Our study suggests a novel pathway for the role of the SWI/SNF complex in tumor suppression. Similar to previous reports, the expression of p53 and p21 was upregulated by Srg3 deficiency (Figure 4) . Although upregulation of p21 proteins apparently seemed to require p53, it could be weakly induced even in the absence of p53 (Figures 5a and b) . p21 seemed not to be controlled at the transcriptional level, but rather stabilized by Srg3 deficiency (Figures 4d-f) . However, the expression of other p53 downstream targets was not significantly affected by Srg3 deficiency, suggesting that p53 in Srg3-KD cells might selectively control specific genes as in the Snf5-null MEFs (Klochendler-Yeivin et al., 2006) . It is of note that the cells with reduced Srg3 expression were protected from DNA damage-induced apoptosis (Figures 3a-c) . This pro-survival effect of Srg3 deficiency was mediated by increased p53 or p21 proteins, because Srg3-KD cells underwent normal cell death in a p53-or p21-null background (Figures 5c and d) . These results suggest that cells with inactivating mutations of Srg3 loci may not be efficiently eliminated in response to DNA damage signals. Instead, they may survive with genomic abnormalities through Tumor suppressor function of Srg3 via p21 regulation J Ahn et al anti-apoptotic functions of p53 and p21, ultimately undergoing oncogenesis in vivo. Indeed, mice with combined haploinsufficiency of Srg3 and p53 (p53
) were more susceptible to the onset of tumors, mostly sarcomas with similar features to leiomyosarcomas, compared with single heterozygous mice (Figures 6a-d) . Consistent with our hypothesis, the levels of p53 and p21 proteins were maintained at high levels in tumors derived from p53 þ /À Srg3 þ /À mice (Figures 6e and f) . These tumors lacked Srg3 proteins, suggesting that Srg3 alleles might undergo loss of heterozygosity (Figure 6f ). It will be interesting to assess whether blockade of p21 induction inhibits oncogenesis induced by Srg3 deficiency in vivo.
Numerous reports have demonstrated protective effects of p21 against p53-or DNA-damage-induced apoptosis (Polyak et al., 1996; Waldman et al., 1996; Bunz et al., 1998; Chan et al., 2000; Gartel and Tyner, 2002; Shibue et al., 2003; Vousden, 2006) . p53 and p21 can enhance tumorigenesis in vivo under certain circumstances (Wang et al., 1997; Martin-Caballero et al., 2001; De la Cueva et al., 2006) . However, it is unlikely that inactivation of specific subunit of the SWI/SNF complex promotes malignant transformation in a similar way. The spectrum, penetrance, latency, histological locations and characteristic features of the tumors are highly divergent in mice deficient for Brg1, Snf5 and Srg3 (Roberts and Orkin, 2004) . The SWI/SNF complex remains intact and several BRG1 target genes are normally expressed in the absence of SNF5 (Doan et al., 2004) . These data suggest that loss of any specific component of the SWI/SNF complex may not be equivalent in inducing specific types of tumors, and that some subunits may function independently of the whole complex. Therefore, it is possible that upregulation of p53 or p21 can exert distinct effects depending on the cellular context. Future studies are required to resolve these issues.
Materials and methods

Mice and cells Srg3
þ /À and Myc-Srg3 transgenic mice were previously described Han et al., 2008) . p53 À/À mice were originally from the Jackson Laboratory. All animals were on a C57BL/6 background and maintained at animal facility at Seoul National University and all experiments were performed in accordance with institutional and university guidelines. Kaplan-Meier plot was compiled from animals that died or were sacrificed when seriously ill or displaying an obvious tumor mass. WT, Srg3 þ /À or Myc-Srg3 MEFs were prepared at embryonic day 13.5B14.5 from embryos generated by mating of Srg3 þ /À and Myc-Srg3 mice and were maintained in Dulbecco's modified Eagle medium containing 10% fetal bovine serum (WelGENE) supplemented with non-essential amino acids. WT, p53 À/À and p21 À/À MEFs on a Friend virus B background were provided by Dr HW Lee (Yonsei University). NIH3T3 was maintained in Dulbecco's modified Eagle medium containing 10% bovine calf serum (WelGENE). All media were supplemented with penicillin and streptomycin.
DNA constructs
The RNAi construct targeting Srg3 (Srg3-KD) was constructed by inserting the cDNA sequence of Srg3 (positions 1320-1328; 5 0 -CGTGACAGAACAGACCAAT-3 0 ) into pSilencer 1.0-U6 vector (Ambion, Austin, TX, USA). KD of Srg3 in MEFs was mediated by MDH1-PGK-GFP 2.0 retroviral vector (Addgene, Cambridge, MA, USA). Sequence of Srg3 small hairpin RNAs hairpin was as follows: 5 0 -CGTGACA GAACAGACCAATTTCAAGAGAATTGGTCTGTTCTGT CACGTTTTTT-3 0 . FLAG-p53 and Myc-Srg3 expression vectors were described elsewhere (Oh et al., 2008) .
Establishment of cell lines and retroviral transduction
To establish stable NIH3T3 cell lines, 1 mg of pBabe-puro vector was co-transfected with 10 mg of either empty or Srg3-KD vector by calcium-phosphate method. After 48 h, cells were maintained in the presence of puromycin at 0.5 mg/ml for at least 3 weeks. To establish stable MEFs, GP þ E-86 cells (from Dr HY Chung, Hanyang University) were infected with retroviruses obtained from 293GPG (H29D) cells transfected with retroviral constructs with lipofectamine (Invitrogen, Carlsbad, CA, USA). MEFs were transduced with retroviral supernatant from stable GP þ E-86 clones in the presence of 8 mg/ml polybrene for 8 h. After incubation at 37 1C overnight, infection was repeated. Transduction efficiency was measured by flow cytometric detection of green fluorescent protein and was routinely beyond 90%.
Cell proliferation assays
For growth curves, 1 Â 10 4 cells of control or Srg3-KD cells were seeded in duplicate in 60-mm dishes. At the indicated time periods, cells were trypsinized and washed and live cell numbers were determined by trypan blue exclusion.
Genotoxin sensitivity
Cells plated at 2 Â 10 5 cells in 60-mm dish were treated with DOX or ETO at the doses as indicated. Cell death was determined 60 h (DOX) or 30 h (ETO) after treatment by flow cytometric analysis of Annexin-V-stained cells. All experiments were conducted in duplicate and performed at least three times.
Flow cytometry
For cell-cycle analysis, 2 Â 10 6 cells were harvested, pelleted and washed with phosphate-buffered saline. Cells were fixed in ice-cold 90% ethanol. After 4 h, cells were pelleted and rehydrated in 1 ml of phosphate-buffered saline for 15 min at RT. Then, cells were incubated with staining solution containing 0.2 mg/ml propidium iodide (Sigma, St Louis, MO, USA), 0.4 mg/ml RNAse A and 4% NP-40. Flow cytometry was carried out by FACS Canto II (BD Biosciences, San Jose, CA, USA) and analyzed using FACS Diva software (BD Biosciences). For the determination of the rate of cell death, cells were stained with biotin-conjugated Annexin-V (BD biosciences) for 20 min on ice followed by washing with Annexin-V staining buffer (BD biosciences). Cells were stained with Streptavidin-allophycocyanin (BD-biosciences) for 20 min on ice in dark and washed with Annexin-V binding buffer. Flow cytometry was carried out by FACS Canto II and analyzed using FACS Diva software.
Reagents and antibodies DOX (D-1515), ETO (E-1383), cisplatin (P-4394), MG132 (C-2211), anti-FLAG (F-3165), anti-b-actin (A-5441) and anti-BAX (B-8429) antibodies were purchased from Sigma; anti-p53 (sc-6243) and anti-p21 (sc-397) antibodies were Tumor suppressor function of Srg3 via p21 regulation J Ahn et al
